A Study of Initiation Timing of VTE Prevention After Colorectal Cancer Surgery
This project intends to conduct a single-center, prospective, observational cohort study to explore the impact of the timing of drug prophylaxis on the risk of postoperative bleeding and the preventive effect of VTE in the prevention and management of postoperative venous thromboembolism (VTE) after colorectal cancer (
| Condition(s) | Colorectal Cancer |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | This project intends to conduct a single-center, prospective, observational cohort study to explore the impact of the timing of drug prophylaxis on the risk of postoperative bleeding and the preventive effect of VTE in the prevention and management of postoperative venous thromboembolism (VTE) after colorectal cancer (CRC) surgery in Chinese population, and to determine its application and promotion value. The research results of this project can provide useful reference for optimizing the prevention and management of VTE after CRC operation. |
| Who can participate | Inclusion Criteria: * ① Age \> 18 years old; ② The patient was diagnosed with colorectal cancer, and the cTMN stage was cT1-2, N0 or cT3, N0 or any cT, N1-2; (3) The patient was diagnosed with colorectal cancer and was able to receive radical surgery (laparoscopic or open surgery). The expected operation time was \>45 minutes, and the expected postoperative survival time was \>6 months. ④ The patient or guardian agrees to the study plan and signs the informed consent. Exclusion Criteria: * ① Renal insufficiency (CrCl\<30 mL/min) or hepatic insufficiency (ALT\> 3 times the upper limit of normal); * The patient was diagnosed with colorectal cancer with a cTMN stage of cT4 and/or local unresectable lesions. Unresectable local recurrent lesions included: (1) extensive lateral pelvic wall invas |
| Ages | 18 Years to 110 Years |
| Sex | All |
| Lead sponsor | RenJi Hospital |
| Locations | Shanghai, Shanghai Municipality, China |
| Start date | 2024-02-01 |
| NCT ID | NCT06259149 |
| Official listing | https://clinicaltrials.gov/study/NCT06259149 |